DHPC – Mifegyne (Mifepristonum)

Safety-related information for the product Mifegyne, Tablets 200mg and Mifegyne, Tablets 600mg

22.12.2023
Preparation Mifegyne, Tablets
Registration number 55205
Active ingredient

mifepristonum

Authorization holder Nordic Pharma GmbH

The current 200mg and 600mg packages on the Swiss market do not contain the most recently approved Patient Information Leaflet.

The new adverse event Acute Generalized exanthematous pustulosis (AGEP) is missing under section “Possible side effects’’ of the leaflet.

For more information, please refer to the company's information letter.